Enteris BioPharma, Inc.
83 Fulton Street
Boonton, NJ 07005
T: (973) 453-3520
E: info@enterisbiopharma.com
W: www.enterisbiopharma.com
LinkedIn: https://www.linkedin.com/company/3194623/


The Preferred Partner in the Oral Delivery of BCS III and BCS IV Compounds.

Enteris BioPharma is a clinical stage biopharmaceutical company offering innovative formulation solutions built around its proprietary oral drug delivery technologies. In addition to its formulation development expertise, Enteris BioPharma has a 32,000 square-foot GMP facility in Boonton, New Jersey, offering an expanding range of manufacturing and development services.

Enteris BioPharma operates as an independent, wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH). Since its founding in 2013, Enteris has advanced into the clinic multiple internal and external programs leveraging its Peptelligence® platform. The technology has been developed and proven effective over the last decade to enable the oral delivery of BCS III and IV compounds that suffer from poor solubility and permeation, resulting in low oral bioavailability including peptides, peptidomimetics, and small molecules. .

Enteris’s formulation technology is made up of two key components, the first is a permeation enhancer, which loosens tight junctions in the intestinal enterocytes and allows paracellular transport. The permeation enhancer, a surfactant, also acts as a great solubilizing agent. The other main excipient, citric acid, also plays an active, multifunctional role in transport by acting as a calcium chelator and membrane permeation enhancer, a pH-lowering agent that increases absorptive flux, and a membrane wetting/charge dispersal agent.

For more information about the Peptelligence® oral formulation technology please download our brochure: https://enterisbiopharma.com/download-peptelligence-brochure/